In the last trading session, 2.09 million Aquestive Therapeutics Inc (NASDAQ:AQST) shares changed hands as the company’s beta touched 2.66. With the company’s per share price at $4.39 changed hands at -$0.42 or -8.73% during last session, the market valuation stood at $400.27M. AQST’s last price was a discount, traded about -41.91% off its 52-week high of $6.23. The share price had its 52-week low at $1.84, which suggests the last value was 58.09% up since then. When we look at Aquestive Therapeutics Inc’s average trading volume, we note the 10-day average is 1.39 million shares, with the 3-month average coming to 1.40 million.
Analysts gave the Aquestive Therapeutics Inc (AQST) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.12. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended AQST as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Aquestive Therapeutics Inc’s EPS for the current quarter is expected to be -0.13.
Aquestive Therapeutics Inc (NASDAQ:AQST) trade information
Instantly AQST was in red as seen at the end of in last trading. With action -8.73%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 117.33%, with the 5-day performance at -8.73% in the red. However, in the 30-day time frame, Aquestive Therapeutics Inc (NASDAQ:AQST) is -20.47% down. Looking at the short shares, we see there were 9.97 million shares sold at short interest cover period of 6.12 days.
The consensus price target for the stock as assigned by Wall Street analysts is 10, meaning bulls need an upside of 56.1% from its current market value. According to analyst projections, AQST’s forecast low is 9 with 12 as the target high. To hit the forecast high, the stock’s price needs a -173.35% plunge from its current level, while the stock would need to soar -105.01% for it to hit the projected low.
Aquestive Therapeutics Inc (AQST) estimates and forecasts
Data shows that the Aquestive Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 48.81% over the past 6 months, a -246.15% in annual growth rate that is considerably lower than the industry average of 16.60%. Year-over-year growth is forecast to reach 13.38% up from the last financial year.
Consensus estimates given by 8 financial analysts project the company’s revenue in the current quarter to hit an average of 13.13M. 5 analysts are of the opinion that Aquestive Therapeutics Inc’s revenue for the current quarter will be 13.08M. The company’s revenue for the corresponding quarters a year ago was 13.21M and 12.05M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -0.60%. The estimates for the next quarter sales put growth at 8.52%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 46.61%. The 2024 estimates are for Aquestive Therapeutics Inc earnings to decrease by -234.62%.
AQST Dividends
Aquestive Therapeutics Inc is expected to release its next quarterly earnings report in January.
Aquestive Therapeutics Inc (NASDAQ:AQST)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 5.01% of Aquestive Therapeutics Inc shares while 55.36% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 58.28%. There are 55.36% institutions holding the Aquestive Therapeutics Inc stock share, with BRATTON CAPITAL MANAGEMENT, L.P. the top institutional holder. As of 2024-06-30, the company held 13.3274% of the shares, roughly 9.81 million AQST shares worth $25.51 million.
VR ADVISER, LLC holds the second largest percentage of outstanding shares, with 7.5468% or 5.56 million shares worth $14.44 million as of 2024-06-30.
